OPKO Health, Inc. (OPK)
Largest Insider Buys in Sector
OPK Stock Price History Chart
OPK Stock Performance
About OPKO Health, Inc.
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units; and a novel diagnostic instrument system to provide blood test results in the point-of-care setting, as well as 4Kscore prostate cancer testing services. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and associated obesity that is in Phase IIb trials; and hGH-CTP, a once-weekly human growth hormone injection that completed Phase III clinical trial in partnership with Pfizer, Inc. This segment develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins. The company also offers specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and imports, markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. In addition, it operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.
Insider Activity of OPKO Health, Inc.
Over the last 12 months, insiders at OPKO Health, Inc. have bought $10.97M and sold $0 worth of OPKO Health, Inc. stock.
On average, over the past 5 years, insiders at OPKO Health, Inc. have bought $9.54M and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: FROST PHILLIP MD ET AL (CEO & Chairman) — $79.16M. Zerhouni Elias A. (Vice Chairman and President) — $1.03M. HSIAO JANE PH D (Vice Chairman & CTO) — $546,797.
The last purchase of 199,072 shares for transaction amount of $305,376 was made by FROST PHILLIP MD ET AL (CEO & Chairman) on 2024‑11‑29.
List of Insider Buy and Sell Transactions, OPKO Health, Inc.
| 2024-11-29 | CEO & Chairman | 199,072 0.0291% | $1.53 | $305,376 | +0.39% | |||
| 2024-11-22 | CEO & Chairman | 100,000 0.0147% | $1.59 | $159,000 | -0.95% | |||
| 2024-11-14 | CEO & Chairman | 100,000 0.0146% | $1.62 | $161,980 | +1.25% | |||
| 2024-11-08 | CEO & Chairman | 280,183 0.0399% | $1.50 | $421,535 | +3.95% | |||
| 2024-05-23 | CEO & Chairman | 100,000 0.0142% | $1.27 | $126,937 | +16.41% | |||
| 2024-05-17 | CEO & Chairman | 163,997 0.0229% | $1.29 | $211,195 | +13.36% | |||
| 2024-03-18 | CEO & Chairman | 500,000 0.0725% | $0.87 | $437,100 | +62.91% | |||
| 2024-03-14 | CEO & Chairman | 500,000 0.0693% | $0.89 | $444,300 | +59.25% | |||
| 2024-03-13 | CEO & Chairman | 500,000 0.0723% | $0.93 | $463,750 | +50.93% | |||
| 2024-03-12 | CEO & Chairman | 600,000 0.0865% | $0.93 | $559,380 | +50.88% | |||
| 2024-02-28 | CEO & Chairman | 500,000 0.0718% | $0.99 | $496,150 | +39.02% | |||
| 2024-02-21 | CEO & Chairman | 1M 0.1283% | $0.99 | $991,700 | +34.65% | |||
| 2024-02-07 | CEO & Chairman | 1.5M 0.1855% | $0.98 | $1.46M | +35.00% | |||
| 2024-01-29 | director | 30,000 0.0038% | $0.99 | $29,838 | +29.47% | |||
| 2024-01-19 | CEO & Chairman | 500,000 0.0634% | $0.98 | $488,650 | +32.80% | |||
| 2024-01-18 | CEO & Chairman | 400,000 0.0506% | $0.97 | $386,200 | +34.50% | |||
| 2024-01-17 | Vice Chairman & CTO | 150,000 0.0187% | $0.95 | $142,500 | +34.64% | |||
| 2024-01-16 | CEO & Chairman | 1M 0.1308% | $0.95 | $954,300 | +40.01% | |||
| 2024-01-11 | CEO & Chairman | 511,531 0.0649% | $0.94 | $480,379 | +36.68% | |||
| 2024-01-08 | Chief Innovation Officer | 216,184 0.026% | $0.93 | $200,427 | +32.73% |
Insider Historical Profitability
| FROST PHILLIP MD ET AL | CEO & Chairman | 211911477 31.0501% | $1.54 | 1147 | 0 | +10.39% |
| HSIAO JANE PH D | Vice Chairman & CTO | 27999880 4.1026% | $1.54 | 27 | 0 | +7.49% |
| Zerhouni Elias A. | Vice Chairman and President | 20327814 2.9785% | $1.54 | 2 | 0 | <0.0001% |
| Rubin Steven D | Executive VP-Administration | 6187732 0.9066% | $1.54 | 15 | 2 | <0.0001% |
| PAGANELLI JOHN A | director | 384340 0.0563% | $1.54 | 6 | 0 | <0.0001% |
| Nabel Gary J. | Chief Innovation Officer | 351442 0.0515% | $1.54 | 4 | 0 | <0.0001% |
| PFENNIGER RICHARD C JR | director | 325000 0.0476% | $1.54 | 5 | 0 | +12.04% |
| KRASNO RICHARD M | director | 103333 0.0151% | $1.54 | 1 | 0 | |
| Frost Gamma Investments Trust | director | 198131694 29.031% | $1.54 | 21 | 0 | <0.0001% |
| Fishel Robert Scott | director | 4120728 0.6038% | $1.54 | 10 | 0 | +1.68% |
| BARON ROBERT A | director | 284088 0.0416% | $1.54 | 3 | 2 | <0.0001% |
| Logal Adam | Sr. Vice President, CFO | 179162 0.0263% | $1.54 | 4 | 3 | <0.0001% |
| LERNER RICHARD A | director | 166172 0.0243% | $1.54 | 6 | 0 | <0.0001% |
| Cohen Jon R | SVP OPKO; Exec Chairman BRLI | 125000 0.0183% | $1.54 | 1 | 0 | +4.52% |
| Japour Anthony J | director | 1000 0.0001% | $1.54 | 2 | 0 | +171.36% |
Institutional Investor Ownership
| BlackRock | $39.87M | 4.77 | 33.23M | -10.11% | -$4.48M | <0.01 | |
| The Vanguard Group | $35.4M | 4.23 | 29.5M | -25.79% | -$12.3M | <0.01 | |
| State Street | $12.24M | 1.46 | 10.2M | +9.63% | +$1.08M | <0.01 | |
| Geode Capital Management | $11.97M | 1.43 | 9.97M | +2.6% | +$302,659.93 | <0.01 | |
| Charles Schwab | $6.97M | 0.83 | 5.81M | +1.32% | +$90,717.60 | <0.01 | |
| Helm Capital Management LLC | $5.92M | 0.71 | 4.94M | New | +$5.92M | 0.18 | |
| Northern Trust | $5.73M | 0.69 | 4.77M | -5.22% | -$315,634.79 | <0.01 | |
| Portolan Capital Management | $3.89M | 0.47 | 3.24M | +95.06% | +$1.9M | 0.3 | |
| Goldman Sachs | $3.74M | 0.45 | 3.12M | +7.13% | +$248,990.32 | <0.01 | |
| Voya Investment Management LLC | $3.71M | 0.44 | 3.09M | +77.47% | +$1.62M | <0.01 | |
| Dimensional Fund Advisors | $3.51M | 0.42 | 2.92M | -15.3% | -$633,151.16 | <0.01 | |
| D. E. Shaw & Co. | $3.18M | 0.38 | 2.65M | -54.71% | -$3.84M | <0.01 | |
| Hrt Financial Llc | $2.06M | 0.25 | 1.72M | +399.47% | +$1.65M | 0.01 | |
| Two Sigma | $1.96M | 0.24 | 1.63M | +68.73% | +$799,046.24 | <0.01 | |
| Allianz Asset Management Gmbh | $1.93M | 0.23 | 1.61M | +110.16% | +$1.01M | <0.01 | |
| JPMorgan Chase | $1.91M | 0.23 | 1.59M | -18.09% | -$422,140.67 | <0.0001 | |
| Invesco | $1.87M | 0.22 | 1.56M | -71.69% | -$4.73M | <0.0001 | |
| Citigroup | $1.83M | 0.22 | 1.52M | -1.7% | -$31,609.20 | <0.01 | |
| BNY Mellon | $1.76M | 0.21 | 1.47M | -9.05% | -$175,228.70 | <0.0001 | |
| Renaissance Technologies | $1.65M | 0.2 | 1.38M | New | +$1.65M | <0.01 | |
| Jane Street Capital | $1.59M | 0.19 | 1.32M | +269.91% | +$1.16M | <0.01 | |
| Awm Investment Company Inc | $1.56M | 0.19 | 1.3M | +18.18% | +$240,000.00 | 0.24 | |
| Morgan Stanley | $1.56M | 0.19 | 1.3M | -30.41% | -$682,457.74 | <0.0001 | |
| Assenagon Asset Management S.A. | $1.5M | 0.18 | 1.25M | +107.16% | +$777,141.89 | <0.01 | |
| Intrinsic Edge Capital Management Llc | $1.44M | 0.17 | 1.2M | +20% | +$240,000.00 | 0.12 | |
| Two Sigma Advisers LP | $1.43M | 0.17 | 1.19M | +4.92% | +$67,079.98 | <0.01 | |
| Nuveen | $1.26M | 0.15 | 1.05M | -8.52% | -$117,278.36 | <0.0001 | |
| UBS | $1.24M | 0.15 | 1.04M | -26.65% | -$451,980.36 | <0.0001 | |
| Credit Suisse | $1.12M | 0.13 | 937,395 | +4.62% | +$49,652.40 | <0.01 | |
| Wilbanks Smith & Thomas Asset Management LLC | $1.05M | 0.13 | 878,824 | +568.92% | +$896,932.97 | 0.03 | |
| Swiss National Bank | $1.01M | 0.12 | 837,855 | 0% | +$0 | <0.01 | |
| Millennium Management LLC | $935,316.00 | 0.11 | 779,430 | +30.68% | +$219,583.20 | <0.01 | |
| Jupiter Fund Management | $918,238.00 | 0.11 | 765,198 | 0% | +$0 | <0.01 | |
| RhumbLine Advisers | $800,903.00 | 0.1 | 667,426 | +2.68% | +$20,890.59 | <0.01 | |
| AllianceBernstein | $684,131.00 | 0.08 | 570,109 | 0% | +$0 | <0.0001 | |
| Alps Advisors Inc | $589,932.00 | 0.07 | 491,610 | -8.36% | -$53,845.20 | <0.01 | |
| Engineers Gate Manager Lp | $590,456.00 | 0.07 | 492,047 | +53.56% | +$205,953.46 | 0.01 | |
| Barclays | $533,000.00 | 0.06 | 444,112 | -42.18% | -$388,807.05 | <0.0001 | |
| T. Rowe Price | $536,000.00 | 0.06 | 445,981 | +4.13% | +$21,237.80 | <0.0001 | |
| CalSTRS | $507,212.00 | 0.06 | 422,677 | -5% | -$26,693.98 | <0.01 | |
| Cantor Fitzgerald L P | $718,694.00 | 0.06 | 425,412 | New | +$718,694.00 | 0.01 | |
| Legal & General | $502,322.00 | 0.06 | 418,602 | 0% | +$0 | <0.0001 | |
| Ubs Asset Management Americas Inc | $481,428.00 | 0.06 | 401,189 | 0% | +$0 | <0.0001 | |
| Bank of America | $473,783.00 | 0.06 | 394,819 | -3.24% | -$15,883.21 | <0.0001 | |
| First Trust | $441,792.00 | 0.05 | 368,160 | +20.42% | +$74,914.80 | <0.0001 | |
| Susquehanna International Group | $371,705.00 | 0.04 | 309,754 | -37.6% | -$223,971.72 | <0.0001 | |
| Simplex Trading Llc | $328,000.00 | 0.04 | 273,551 | +84.38% | +$150,109.66 | 0.01 | |
| Royal Bank of Canada | $314,000.00 | 0.04 | 262,507 | -13.77% | -$50,123.83 | <0.0001 | |
| Tudor Investment Corp Et Al | $293,785.00 | 0.04 | 244,821 | 0% | +$0 | <0.01 | |
| Citadel Advisors LLC | $268,063.00 | 0.03 | 223,386 | -45.32% | -$222,197.83 | <0.0001 |